Numotion: In brief: Numotion reports data incident, Abbott launches app

PHOENIX - Numotion recently learned that certain employee email accounts were accessed without authorization on several occasions between Sept. 2, 2024, and Nov. 18, 2024, the company said in a Notice of Data Security Incident posted on its website. In the notice, the company states: "Numotion has no reason to believe that anyone was trying to access personal information in the accounts, and there is no indication that any information has been used for fraud or identity theft. Nevertheless, out of an abundance of caution, Numotion undertook an extensive review of the emails that may have been accessed. On January 22, 2025, we determined that the emails at-issue contained some customers' information." The type of information that may have been viewed varied, but could have included names, dates of birth, product information, payment and financial account information, health insurance information, medical information, and for a minority of individuals social security numbers and driver's license numbers, Numotion stated. The company has sent letters to potentially involved individuals for whom it has a valid mailing address and has arranged for complimentary identity theft protection services for those individuals whose Social Security numbers were involved in the incident. In an email to HME News the company said: "At Numotion, we take data security seriously and prioritize ongoing efforts to minimize risks, employing industry-standard practices. Following this incident, we conducted a comprehensive review of our security policies and implemented several enhanced measures to further strengthen our defenses." For further information and assistance, please call the dedicated call center that Numotion has engaged to address questions. The call center can be reached at 866-450-2357 from 8:00 am - 5:30 pm Central Time, Monday - Friday excluding major US holidays. Medtronic sensor receives FDA clearance GALWAY, Ireland - Medtronic has received clearance from the U.S. Food and Drug Administration for the Simplera Sync sensor for use with the MiniMed 780G system. With this approval, the MiniMed 780G system now offers more flexibility for users of the company's most advanced insulin delivery system featuring Meal Detection technology with both the Guardian 4 sensor and Simplera Sync sensor. The Simplera Sync is a disposable, all-in-one sensor that requires no fingersticks with SmartGuard or overtape and features a simple, two-step insertion process. "We're committed to driving innovation that makes life easier for those living with diabetes so they can forget about their diabetes as much as possible throughout the day," said Que Dallara, EVP and president of Medtronic Diabetes. "Our MiniMed 780G system delivers advanced diabetes technology for so many around the world, and we're excited to continue evolving this experience with expanded CGM options -including our Simplera Sync sensor, which we look forward to bringing to people living with diabetes in the U.S." A limited launch of the Simplera Sync sensor will begin in the U.S. in the fall of 2025. Biosensor tech company secures $100M investment SAN DIEGO - Biolinq, a healthcare technology company of biosensors, has received a $100 million Series C financing led by Alpha Wave Ventures, with participation from existing investors RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical and Features Capital. The funding will support Biolinq through the US regulatory approval process as the company prepares to bring the first autonomous intradermal glucose sensor to market. Biolinq's initial product is a wearable biosensor powered by an array of tiny electrochemical sensors that measure glucose levels continuously just beneath the skin's surface. "This financing will bolster Biolinq's commercial readiness efforts while we pursue regulatory approval for the first intradermal glucose sensor that incorporates activity and sleep information into a single wearable device," said Rich Yang, CEO. "Our team has spent the last decade developing a biosensor platform designed to inspire healthier living by providing context around a person's metabolic health." Biolinq's glucose sensor patch placed on the upper forearm features a color-changing indicator light, providing users with real-time feedback to stay informed about glucose excursions. The company's first-generation glucose sensor is designed for ease of use and reliability leveraging a biosensing platform that enables future multi-analyte sensing capabilities. Florida woman pleads guilty to braces fraud CONCORD, N.H. - A Florida woman plead guilty April 15 in federal court in Concord in connection with her role in a conspiracy to defraud Medicare of $3.3 million. Yolanda Dupont, 38, of New Port Richey, Fla., plead guilty to one count of conspiracy to commit health care fraud.According to court documents, Dupont and her co-conspirators owned and operated Allstar Medical Supply Corp., a purported durable medical equipment business in New Hampshire selling orthotic braces. As part of the conspiracy, Dupont served as the nominee owner of the business to conceal the identities of the true owners. During the conspiracy, Dupont and her co-conspirators submitted, or caused the submission of, approximately $3.3 million in false and fraudulent claims for orthotic braces to Medicare. Medicare paid at least $1.6 million to Dupont and her co-conspirators for these claims. Ultimately, Medicare beneficiaries received orthotic braces that were medically unnecessary, ineligible for reimbursement, and often not wanted or needed. Dupont faces the possibility of a sentence of no greater than 10 years in prison, three years of supervised release, and a fine of $250,000 or twice the pecuniary gain. Sentencing is scheduled for July 22, 2025. Heartland extends early bird pricing, offers generous refund WATERLOO, Iowa - The VGM Heartland Conference is extending its early bird pricing until April 30. Conference registration includes all meals, onsite transportation, and comes with a 100% satisfaction guarantee. "We recognize plans change and to provide you peace of mind, we revised our refund policy," said Jill Blaser, conference chair. "If circumstances prevent you from attending, we will fully refund your registration through June 1. This policy change underscores our commitment to supporting attendees and ensuring their participation in this vital industry event." This year's event offers more than 60 educational sessions and panel discussions to attend and earn contact hours/CEUs on topics such as billing and compliance, technology and security, business operations, complex rehab technology, leadership and people strategy, respiratory, sales, marketing, and integrated health and policy topics, an exhibit hall and networking opportunities. Related: See what Jill Blaser had to say about this year's event. Greg LoPresti to chair NHIA board of directors ALEXANDRIA, Va. -TheNational Home Infusion Association(NHIA) is pleased to announce that Greg LoPresti, CEO Upstate HomeCare has been named chair of its board of directors. LoPresti and the full 2025-2026 Board of Directors were installed at the NHIA Annual Conference in Washington, D.C. earlier this month. John Rademacher, CEO of Option Care Health, who completed his term as board chair, remains on the executive committee as past chair. "We welcome Greg's leadership and expertise at a critical time when the association continues to build on its mission. His industry knowledge and perspective will be key advantages as NHIA advocates for appropriate coverage for infusion services and improved access to care for all patients," said Connie Sullivan, NHIA president and CEO. LoPresti addressed NHIA conference attendees, telling them: "I believe that we're at an inflection point. The rising needs and costs associated with health care are coming to the point where we have to find a common solution. Although home infusion has a small voice, compared to hospitals, physicians, and other large cost centers, we're closer than ever to standing up a workable Medicare benefit." Abbott launches Libre app ABBOTT PARK, Ill. - Abbott has launched the new Libre app in the U.S., making it easier than ever for users of both the FreeStyle Libre 2 and FreeStyle Libre 3 systems to track glucose readings and insights. Features include: automatic data streaming; silent mode, in which users of the FreeStyle Libre 3 can silence alarms for up to six hours; optional gradual alarms to discreetly alert users to high or low glucose levels; and easier navigation. "By listening to our customers, we developed a universal app with enhanced features to make living with diabetes easier," said Badia Boudaiffa, vice president North America commercial operations for Abbott's diabetes care business. "With the new Libre app, Libre users will experience a more user-friendly interface that makes tracking glucose readings and insights easier and streamlines care." The app is available now in the U.S. with Android and iOS systems. Users can download the app to their smartphone from the Apple Store or Google Play. Related: Abbott last year opened a new manufacturing facility for its FreeStyle 3 sensors in Kilkenny, Ireland. Short takes: Rehab fly-in, NCPA video iNRRTS, NCART and U.S. Rehab are asking complex rehab stakeholders to mark their calendars for the 2025 Congressional Fly-in, scheduled for Sept. 16-17. More information is coming soon...The National Community Pharmacists Association has released two new episodes of its educational reality series, "Show Me," this time diving deep into maternal vaccination programs. "Show Me," which NCPA debuted in 2022, is a video series styled after popular TV makeover shows, only these stars are real pharmacists who need help getting a certain aspect of their business on track.